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ABSTRACT
Objective: The national essential drug committee in Thailand
suggested that only one of thiazolidinediones be included in
hospital formulary but little was know about their cost-
effectiveness values.This study aims todetermine an incremen-
tal cost-effectiveness ratio of pioglitazone 45 mg compared
with rosiglitazone 8 mg in uncontrolled type 2 diabetic
patients receiving sulfonylureas and metformin in Thailand.
Methods: A Markov diabetes model (Center for Outcome
Research model) was used in this study. Baseline character-
istics of patients were based on Thai diabetes registry project.
Costs of diabetes were calculated mainly from Buddhachi-
naraj hospital. Nonspeciﬁc mortality rate and transition
probabilities of death from renal replacement therapy were
obtained from Thai sources. Clinical effectiveness of thiazo-
lidinediones was retrieved from a meta-analysis. All analyses
were based on the government hospital policymaker perspec-
tive. Both cost and outcomes were discounted with the rate of
3%. Base-case analyses were analyzed as incremental cost per
quality-adjusted life year (QALY) gained. A series of sensitive
analyses were performed.
Results: In base-case analysis, the pioglitazone group had a
better clinical outcomes and higher lifetime costs. The incre-
mental cost per QALY gained was 186,246 baht (US$ 5389).
The acceptability curves showed that the probability of
pioglitazone being cost-effective was 29% at the willingness
to pay of one time of Thai gross domestic product per capita
(GDP per capita). The effect of pioglitazone on %HbA1c
decrease was the most sensitive to the ﬁnal outcomes.
Conclusions: Our ﬁndings showed that in type 2 diabetic
patients who cannot control their blood glucose under the
combination of sulfonylurea and metformin, the use of
pioglitazone 45 mg fell in the cost-effective range recom-
mended by World Health Organization (one to three times of
GDP per capita) on average, compared to rosiglitazone 8 mg.
Nevertheless, based on sensitivity analysis, its probability of
being cost-effective was quite low. Hospital policymakers
may consider our ﬁndings as part of information for the
decision-making process.
Keywords: cost-effectiveness analysis, pioglitazone, rosiglita-
zone, thiazolidinediones.
Introduction
Diabetes is a chronic disease associated with increases
in morbidity, mortality, and health-care expenditures
worldwide [1]. Prevalence of diabetes diseases in Thai-
land is also high. The estimated national prevalence of
Diabetes in Thai adult (age over 35) in year 2000 was
up to 9.6% or 2.4 million people [2]. The Diabetes
Registry Project 2003 [3] reported that among 9419
diabetes patients in Thailand had blindness due
to diabetes (1.5%), history of amputation (1.6%),
coronary diseases (8.5%) and cerebral vascular dis-
eases (4.5%). In 2002, diabetes was one of the four
leading chronic diseases that caused 29 million deaths
worldwide [4]. The health-care expenditure on treat-
ment of diabetes is high in many countries. In Japan,
the health-care expenditures on diabetes are $ 8 bil-
lions or 4% of total health-care expenditures of the
government in 1996 [5] and up to $ 98 billion in the
USA in 1997 [6].
The main goal of treating diabetic patients is to
prevent macro- and microvascular complications by
controlling blood glucose level. The United Kingdom
Prospective Diabetes Study (UKPDS) [7] indicated
that controlling blood glucose level could delay the
progress of microvascular complications in type 2
diabetes. Although nonpharmacologic treatment can
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improve the glycemic control, the UKPDS reported
that not more than 8% of diabetes patients can control
their blood glucose with nonpharmacologic therapy
within 9 years. Oral hypoglycemic drug treatment
should be used in the next step.
Thiazolidinedione is an oral antihyperglycemic
agent that can reduce insulin resistance in peripheral
tissues and decrease hepatic glucose production [8].
There are two drugs in this class currently available in
the market: rosiglitazone and pioglitazone. In the large
clinical trial of pioglitazone, the PROactive (the Pro-
spective Pioglitazone Clinical Trial in Macrovascular
Events) [9], the use of pioglitazone could signiﬁcantly
reduce a composite secondary end point of all-cause
mortality, stroke, and myocardial infarction with the
relative risk reduction of 16%. Therefore, adding
thiazolidinedione may help delay the progression of
macrovascular diseases including myocardial infarc-
tion and stroke which the combination of sulfonylurea
and metformin cannot [7].
From the hospital policymaker perspective, both
cost and effectiveness of the interventions should be
considered when a decision to include an intervention
into hospital formulary needs to be made. There are
many cost-effectiveness studies in thiazolidinediones
conducted in other countries, but not in Thailand
[10–15]. Only two studies compared the cost-
effectiveness between rosiglitazone and pioglitazone
[12,15], but both studies did not base their effective-
ness on meta-analysis. In addition, the results in one
country cannot be applied to other countries because
of the differences in health-care systems and resource
utilization pattern. A cost-effectiveness study of thia-
zolidinediones has not been conducted in Thailand.
In this study, we determined an incremental cost-
effectiveness ratio of the maximal dose of pioglitazone
compared with the maximal dose of rosiglitazone in
patients who cannot control their blood sugar with
sulfonylureas and metformin. We adapted the Center
for Outcome Research (CORE) diabetes model by
Thai data to use as an analytical instrument in this
study.
Methods
CORE Diabetes Model
The CORE diabetes model is the analytical tool that
was used in this study. The model consists of 15 sub-
models including angina, cataract, congestive heart
failure, foot ulcer and amputation, hypoglycemia,
ketoacidosis, lactic acidosis, macular edema, myocar-
dial infarction, nephropathy, neuropathy, peripheral
vascular disease, retinopathy, stroke, and nonspeciﬁc
mortality. Each submodel is a Markov model using
Monte Carlo simulation using probabilities derived
from published sources. The model can predict the
long-term costs and outcomes in diabetes patients
based on many large clinical and epidemiological
studies that are currently available [16]. The model
analyses data by taking into account of baseline char-
acteristics of a cohort, clinical effectiveness and costs
of intervention, and transition probabilities of each
diabetes complication progressions. The ﬁnal out-
comes are reported as life expectancy, quality-adjusted
life expectancy, cumulative incidence of each diabetes
complications, and total lifetime costs of the diabetes
populations.
Interventions Compared
The interventions compared in this study are pioglita-
zone and rosiglitazone used in type 2 diabetic patients
who cannot control their blood glucose under the com-
bination of sulfonylurea and metformin. The dose
regimen of pioglitazone was 45 mg orally taken once
daily, while the dose regimen of rosiglitazone was 8 mg
taken orally once daily. These two regimens were the
full dose of each thiazolidinedione which are capable
of achieving the best glycemic control level of each
product. Clinical effectiveness of both regimens were
derived form a meta-analytic study conducted by
Chiquette and colleague (Table 1) [17].
Cohort
Baseline characteristics of our hypothetical cohort
were based on Thai Diabetes Registry Report (TDRP)
[3]. This project is a multicenter registry of 9419 dia-
betic patients receiving medical care in diabetic clinics
of 11 tertiary centers in Bangkok and major provinces.
The registry data were collected from April to Decem-
ber 2003. Almost all patients (94.6%) were type 2
diabetic patients. Some characteristics that were not
reported in TDRP were retrieved from other publica-
tion related with Thai population (Table 2).
Costs and Perspective
The government policymaker perspective was taken in
this study by considering only direct medical costs of
Table 1 Clinical effectiveness of the treatment used in the analysis
Interventions HbA1c (%) HDL (mg/dL) Tot Chol (mg/dL) Ref.
Pioglitazone 45 mg (combination*) Mean (95% CI) -1.56 (-1.16 to -1.96) +4.55 (+3.61 to +5.48) -0.09 (-0.13 to +0.13) [17]
Rosiglitazone 8 mg (combination*) Mean (95% CI) -1.26 (-1.48 to -1.04) +2.71 (+2.01 to +3.42) +21.3 (+17.7 to +24.9) [17]
*Combination means the use of thiazolidinediones combined with either sulfonylurea or metformin.
HDL, high density lipoprotein; Ref., references;Tot Chol, total cholesterol.
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each competing treatment. The direct medical costs
include cost of medications, cost of laboratory moni-
toring, and cost of managing diabetes-related compli-
cations incurred either inpatient or outpatient services.
The estimated costs of diabetes-related complications
in Thailand were derived from different sources.
Most of diabetic complication costs were calculated
from Buddhachinaraj hospital’s database (Phitsanu-
lok, Thailand). A total of 12,902 type 2 diabetic
patients were identiﬁed by ICD-10 (International Clas-
siﬁcation of Disease version 10) diagnosis or the use of
medications speciﬁc for diabetes between June 2001
and July 2005. Other complication costs that could be
not calculated from the hospital database were derived
from Thai published literature, expert opinions,
and DRGs (Diagnosis-Related Groups) guidebook
(Table 3). Based on the average cost derived from the
Drug and Medical Supply information center [18], the
daily cost of pioglitazone and rosiglitazone was 107.87
baht (US$3.12) and 86.08 baht (US$2.49), respec-
tively. All costs were adjusted to 2004 value. To
present the results in US$, we used the currency
exchange rate of April 23, 2007, 34.56 baht/US$1 [19]
refer to Bank of Thailand website (http://www.bot.or.
th/bothomepage/index/index_e.asp).
Transition Probabilities
Most of diabetic complication transition probabilities
were based on the CORE model default [16] except
probability value of nonspeciﬁc mortality and death
related to hemodialysis and peritoneal dialysis. Non-
speciﬁc mortality probability values in the model were
replaced by age-speciﬁc mortality data in Thai popu-
lation [20]. Probabilities values of death related to
hemodialysis and peritoneal dialysis were derived from
Thai renal registry project 2003 [21].
Time Horizon
Time horizon of the simulation was 40 years. We used
40 years to conﬁrm that the simulation would cover
the average life time of our cohort.
Discounting
Costs and clinical outcomes were discounted at
3% annually in base-case analysis, according to
Table 2 Base line characteristics of the Thai diabetic population
Baseline characteristics
Mean SD Ref.
Start age 59.43 years 13.52 years [3]
Duration of diabetes 10 years 7.61 years [3]
Proportion of male 0.34 [3]
Mean: SD:
HbA1c 7.75% 0.56% Expert opinions
Systolic blood pressure 126.3 mmHg 0 mmHg [2]
Total cholesterol 197.1 mg/dL 42.52 mg/dL [3]
High density lipoprotein cholesterol (HDL) 53.9 mg/dL 15.31 mg/dL [3]
Low density lipoprotein cholesterol (LDL) 114.5 mg/dL 35.76 mg/dL [3]
Triglyceride 150.7 mg/dL 105.4 mg/dL [3]
Body mass index 25.6 kg/m2 4.3 kg/m2 [3]
Proportion
Proportion of myocardial infarction 0.42 [3], database*
Proportion of angina 0.43 [3], database*
Proportion of peripheral vascular disease 0.039 [3]
Proportion of stroke 0.044 [3]
Proportion of congestive heart failure 0.03 Database*
Proportion of atrial ﬁbrillation 0.017 Database*
Alcohol consumption 35 oz/week [32]
Proportion of smoker 0.141 [3]
Cigarettes/day 10.8 [33]
Proportion of left ventricular hypertrophy 0.13 [34]
Proportion of micro albuminuria 0.178 [3]
Proportion of gross protienuria 0.178 [3]
Proportion of end state of renal disease 0.083 [3]
Proportion of background diabetic retinopathy 0.213 [3]
Proportion of proliferative diabetic retinopathy 0.094 [3]
Proportion of severe vision loss 0.015 [3]
Proportion of macular edema 0.022 [35]
Proportion of cataract 0.428 [3]
Proportion of uninfected ulcer 0.059 [3]
Proportion of healed ulcer 0.044 [36]
Proportion of history of amputation 0.016 [3]
Proportion of neuropathy 0.168 [36]
*Buddhachinaraj hospital database.
Ref., references.
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World Health Organization (WHO) guide of cost-
effectiveness analysis [22].
Data Analysis
In the model simulation, each of 1000 nonidentical
patients with different baseline characteristics was run
for 1000 times. The mean incremental costs versus
mean incremental effectiveness of 1000 simulations of
each 1000 patients were used to generate a scatter plot.
Mean of the mean incremental costs versus mean in-
cremental effectiveness of 1000 patients was reported
as the incremental cost-effectiveness ratio.
Sensitivity Analysis
The sensitivity analyses were done by varying some
variables including effects of pioglitazone on %HbA1c
decreasing, effects of pioglitazone on lipid proﬁles,
time horizon that used to run the simulation, drug
treatment costs of the pioglitazone group, and the
discounting rate. In the HbA1c sensitivity analysis, we
use %HbA1c change from baseline in pioglitazone
group between -1.16 and -1.96 (upper bound and
lower bound of the conﬁdent interval of %HbA1c
changing in pioglitazone treatment report in the
Chiqutte’s Meta-analysis [17]). Effects of pioglitazone
on lipid proﬁles were also varied by using upper bound
and lower bound of 95% conﬁdence interval from the
Meta-analysis. Drug treatment cost of the pioglitazone
group was varying by +25% of the pioglitazone treat-
ment cost in base-case. For the sensitivity analysis of
discounting rate, we use the recommendation from
WHO [22] including 0% discount costs and clinical
effects, 0% discount clinical effects and 6% discount
costs, and 6% discount cost and clinical effects.
Finally, we vary time horizon from 10 years to
30 years.
Results
Base-Case Analysis
The results from the base-case analysis showed that
patients in the pioglitazone group had slightly lower
cumulative incidence of diabetes complications than
those in the rosiglitazone group. The incidence of pro-
liferative diabetic retinopathy, end stage renal disease,
amputation ulcer, and myocardial infarction in the
pioglitazone group compared to the rosiglitazone
group was 1.11% versus 1.19%, 5.07% versus
5.42%, 6.64% versus 6.70%, and 15.90% versus
18.50%, respectively. In addition, patients in the
pioglitazone group had longer life expectancy and
quality-adjusted life expectancy compared to the
rosiglitazone group. Life expectancy and quality-
adjusted life expectancy in the pioglitazone group was
0.16 and 0.14 years higher than those in the rosiglita-
zone group, respectively. At the end of the 40 years
Table 3 Thai diabetes-related costs used in the CORE diabetes model
Description of event or state Cost per event or state (baht) References
Annual cost of screening for microalbuminuria 150 Expert opinion*
Annual cost of screening for gross proteinurea 10 Expert opinion*
Annual cost of eye screening 118 [37]
Myocardial infarction, year of event 67,653 Database†
Myocardial infarction, each subsequent year 27,447 Database†
Angina, year of event 67,192 Database†
Angina, each subsequent year 32,323 Database†
Congestive hear failure, year of event 60,801 Database†
Congestive hear failure, each subsequent year 24,779 Database†
Stroke, year of event 63,984 Database†
Stroke, each subsequent year 31,996 Database†
Cost of hemodialysis (HD), year of event 352,665 [31,38]
Annual costs HD, each subsequent year 331,165 [31,38]
Cost of peritoneal dialysis (PD), year of event 408,083 [31]
Annual costs of PD, each subsequent year 361,416 [31]
Cost of renal transplant (RT), year of event 333,228 [39]
Annual costs RT each subsequent year 91,329 [39]
Major hypoglyceamic event 12,472 Database†
Ketoacidosis event 42,375 Database†
Lactic acid event 40,510 Database†
Cost of eye laser treatment 1,756 [37]
Cost of cataract operation 11,403 [40]
Neuropathy, year of event 21,515 Database†
Neuropathy, each subsequent year 24,034 Database†
Amputation (event-based) 76,688 Database†
Amputation Prosthesis (event-based) 2,900 Expert opinion*
Gangrene treatment (monthly-based) 62,245 Database†
Standard uninfected ulcer (monthly-based) 8,371 Database†
*Albuminuria screening costs got from an expert opinion who had worked as the head of Chemical clinic laboratory department, Buddhachinaraj hospital.Amputation prosthesis
cost was cost of artiﬁcial limb that got from the opinions of two experts who had worked at the artiﬁcial limb center at Buddhachinaraj hospital.
†Data were average costs calculated from diabetic patients in Buddhachinaraj hospital database between June 2001 and July 2005.
CORE, Center for Outcome Research.
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simulation, the survival rate of the pioglitazone group
was 0.3% and rosiglitazone group was 0.1%.
The total costs in the pioglitazone group were
higher than the total costs in the rosiglitazone group.
An incremental cost-effectiveness ratio showed that we
had to pay 161,777 Baht (US$ 4681) for one life
year gained or pay 186,246 Baht (US$ 5389) for an
additional quality-adjusted life year (QALY) earned
(Table 4).
The incremental cost-effectiveness scatter plot of
1000 sample generated from mean incremental costs
versus mean incremental effectiveness of 1000 simula-
tion of each 1000 patients (Fig. 1) showed that major-
ity of the cost-effectiveness ratio fell in the upper right
quadrant. This indicates that most simulations showed
that the pioglitazone treatment is both higher costs and
more effective than the rosiglitazone treatment.
When we used the scatter plot to generate an
acceptability curve (Fig. 2), the acceptability curve
show how likely it will be that the pioglitazone treat-
ment is cost-effective for any particular willingness to
pay value. With a willingness to pay value of 110,000
and 33,000 Baht per QALY gained, there is a 29% and
64% probability that the pioglitazone treatment will
be cost-effective compared to the rosiglitazone treat-
ment, respectively.
Sensitivity Analyses
Sensitivity analyses showed that the most inﬂuential
variable was the effect of %HbA1c change. When
varying the effect of %HbA1c change (Fig. 3), the
incremental cost per QALY gained varied from 79,586
to 951,204 baht (US$ 2302–US$ 27,523)/QALY.When
%HbA1c change from pioglitazone using was -1.16%
(lower bound of the conﬁdence interval of %HbA1c
change frompioglitazone used in the base-case analysis)
and %HbA1c change from rosiglitazone using was
-1.26% as in the base-case analysis, the pioglitazone
group remained dominant to rosiglitazone.
Varying other variables for the sensitivity analysis
also affected the ﬁnal outcome but the effects were
less than the effect of %HbA1c change. The cost-
effectiveness values, when using varying discount rates,
fell between 130,224 and 262,681 Baht (US$ 7600)/
QALY. Varying the pioglitazone drug costs by + 25%
showed the incremental cost per QALY fell between
64,329 (US$ 1861) and 308,163 Baht (US$ 8916)/
QALY. The incremental cost-effectiveness ratio was
slightly changed when we varied the effects of piogli-
tazone on lipid proﬁles (Fig. 3). The effects of pio-
glitazone on low density lipoprotein (LDL) and
triglyceride did not affect the cost-effectiveness values.
Varying time horizontal showed that using thiazo-
lidinediones for 40 years was more cost-effective than
10 years and 20 years.
Discussion
Our base-case ﬁndings showed that using pioglitazone,
compared to rosiglitazone, resulted in reduced inci-
dence of long-term complications, improved life
Table 4 Summary of cost and incremental cost-effectiveness
analysis in base-case results
Pioglitazone group Rosiglitazone group
Average total lifetime cost
(baht) (SD)
491,457 (16,202) 465,839 (16,136)
Average life expectancy (years) 9.62 (0.171) 9.47 (0.177)
Average quality adjusted life
year (years)
6.69 (0.124) 6.55 (0.123)
Incremental cost per life
expectancy (baht per life
year gained)
161,777
Incremental cost per quality
adjusted life expectancy
(baht per quality adjusted
life year gained)
186,246
Figure 1 The incremental cost per quality
adjusted life expectancy scatter plot. QALE,
quality adjusted life expectancy.
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expectancy and QALY in type 2 diabetic patients who
have previously failed on treatment with sulfonylurea
or metformin. These clinical beneﬁts of pioglitazone
over rosiglitazone are mostly derived from the better
lipid proﬁle and glycemic control [17] although the
higher cost in the pioglitazone group is mostly due to
the medication cost.
In addition, the sensitivity analysis results demon-
strated that the effects of pioglitazone on %HbA1c
changes from base line were the most sensitive to the
ﬁnal outcomes. This is not surprising as glycemic level
is a strong predictor of developing microvascular and
macrovascular complications [7,23]. In a scenario
when the effects of glycemic control of pioglitazone
were inferior to rosiglitazone (%HbA1c change of
-1.16% vs. -1.26%), the incremental cost per QALY
gained was 951,204 baht (US$ 27,523) per QALY
gained or ﬁve times higher than the incremental cost
per QALY gained in the base-case analysis. The glyce-
mic control results were affected directly with our
interventions. Although life style modiﬁcation was also
a potential effect on glycemic control in a clinical prac-
tice, it did not affect to the results of our analysis. We
assumed that the life style modiﬁcation in both the
pioglitazone group and the rosiglitazone group
were not different. Therefore, our ﬁnal incremental
effectiveness was reﬂected from the difference of effec-
tiveness between both thiazolidinediones only.
Based on the WHO recommendation regarding the
cost-effectiveness thresholds criteria [24–26], an inter-
vention with an incremental cost-effectiveness ratio
less than one or falling between one to three times of
gross domestic product per capita (GDP per capita)
would be deemed very cost-effective and potentially
cost-effective, respectively. On the other hand, an inter-
vention with a cost-effectiveness ratio beyond the three
times of GDP per capita would be interpreted as not
cost-effective. Based on the results of this study, the
incremental cost per QALY gained in our base-case
analysis was 186,246 baht (US$ 5389) per QALYs
which was about 1.7 times of the Thai GDP per capita
(110,000 baht per year) in 2005 ﬁscal year. The results
fell between one to three times GDP per capita. When
we applied the criteria based on WHO recommenda-
tion, the incremental cost-effectiveness ratio in our
study showed that using pioglitazone was likely to be
cost-effective, compared with rosiglitazone.
When taken into account the join probability of
values of the incremental cost and effectiveness simul-
taneously, the cost-effectiveness acceptability curve
graphically presents the probability of being cost-
effective as a function of the maximal willingness to
pay value. The cost-effectiveness acceptability curves
in our study illustrated that the probability per QALY
gained was only 29% at 110,000 baht per QALY
gained and 64% at 330,000 baht per QALY gained
(a value of one and three times of GDP per capita,
respectively). This way of presenting ﬁndings is easy to
understand and provides more meaningful interpreta-
tion, compared to the base-case analysis.
Our cost-effectiveness results were different from
the ﬁndings in previous cost-effectiveness studies
[12,15]. Based on a dossier submission, reported in the
article of Veenstra and colleagues [15], using pioglita-
zone resulted in cost-savings of US$ 6057 in year
2000. Nevertheless, the analysis was performed for
comparing pioglitazone 30 mg and rosiglitazone 4 mg
Figure 2 Acceptability curve. QALY, quality-adjusted life year.
Figure 3 Tornado diagram of the sensitivity
analyses.* *Effect of pioglitazone on %HbA1c,
total cholesterol (T-Chol), and HDL were varied
in the sensitivity analysis, when effect of rosigli-
tazone on each parameters were set as con-
stant as the base case analysis.HDL, high density
lipoprotein.
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in combination with metformin or sulfonylurea [15],
which was different from our study in which a
maximal dose of pioglitazone 45 mg and rosiglitazone
8 mg was studied. Henrikson [12] determined a cost-
effectiveness of thiazolidinedione using Swedish
perspective. The study compared pioglitazone 30 mg
versus rosiglitazone 8 mg in combination with
metformin and found that the incremental cost-
effectiveness ratio was SEK$ 148,561/life years gained
[12]. Both studies were not interpreted cost-
effectiveness by WHO criteria. The cost-effectiveness
interpretation was not a problem in Veenstra et al.
study because they stated that using pioglitazone was
cost-saving [15]. Henrikson study stated that Sweden
authorities were not set threshold values for cost-
effectiveness in health-care expenditure. Henrikson
applied data from the Swedish Road Safety Ofﬁce for
the cost-effectiveness threshold to interpret his result.
The value that could be interpreted as cost-effective in
Henrikson study was not more than SEK$ 430,000 per
life years gained [12]. It was important to note the
model used in both studies was based on the diabetes
model, developed by the Institute for Medical Infor-
matics and Biostatistics (IMIB), which was the original
model version of CORE diabetes model [27].
One limitation of our study was that we calculated
diabetes complication costs mainly from a hospital.
As this hospital is a teaching, tertiary care, govern-
ment hospital, the cost estimates may be different in
other hospitals. Kunaratanapruk and colleagues [28]
reported that the charge was different between the
government hospital in Bangkok and the government
hospital in other provinces in 1995. Total charges of
the accident treatment in out-patient visit in the gov-
ernment hospital in Bangkok were two times higher
than that in the government hospital in outside of
Bangkok [28]. In addition, missing value is commonly
seen in the hospital database [29]. Nevertheless, after
we found that 90% of inpatient room charge was
missing, we could replace the room charge by calcu-
lating average room charges in each year of the hospi-
tal and multiplied it with the length of stay of each
patient to replace the missing data. Coding error was
another problem that can occur in the database. This
problem is also commonly found in the database of
other countries [6]. Given that almost 10,000 observa-
tions were included in our analysis, the effect of wrong
coding was unlikely to be large.
We believe that our results are valid for Thai popu-
lation because of several reasons. First, the transition
probabilities of diabetes complication progression that
used in the model were based on two large, longitudi-
nal cohort studies, The Framingham cohort and
UKPDS studies. These studies had a follow-up period
more than 10 years. They were landmark studies
which the relationship of glycemic control, lipid pro-
ﬁles, and other factors and the risk of developing dia-
betes complications were derived from. Second, the
CORE diabetes model is one of a few models that have
been validated in several clinical studies using different
population including for Asians [30]. Last, many of
Thai speciﬁc data were used to input in our analysis
including baseline characteristic of diabetes patients,
age-speciﬁc mortality, renal replacement therapy spe-
ciﬁc mortality, diabetes complication costs and associ-
ated medical costs.
Several crucial issues need to be considered, when
decision-makers interpreted our ﬁndings. First, our
study determines the effect of maximum dose of piogli-
tazone combination and maximum dose of rosiglita-
zone combination only. Second, this study was
performed using the hospital perspective. The incre-
mental cost-effectiveness ratio may be lower if the
societal perspective is considered. Third, we have to
consider many factors when we decide to choose a
treatment for our organization including the ethical,
and health equity issue. For example, a study of cost-
utility analysis of renal replacement therapy in Thai-
land by Teerawattananon [31] demonstrated that
peritoneal dialysis and hemodialysis are considered not
cost-effective, according to WHO threshold recom-
mendation. This does not mean that the hospital poli-
cymakers should discard the renal replacement therapy
in their organization for budget saving. On the other
hand, government has decided to allow peritoneal
dialysis and hemodialysis to be used in a certain situ-
ation despite the ﬁndings of non–cost-effective.
Conclusion
To our knowledge, this study is the ﬁrst to evaluate the
cost-effectiveness of pioglitazone, compared to rosigli-
tazone, in terms of long-term health outcomes and
economic consequences in the context of Thai health-
care system. Although the base-case analysis found
that the use of pioglitazone fell in the cost-effective
range recommended by WHO cost-effective as thresh-
old criteria (one to three times of GDP per capita), the
acceptability curves demonstrated probability that the
use of pioglitazone was cost-effective were between
29% and 64% at the one time and three times of GDP
per capita, respectively. Nevertheless, if we considered
using pioglitazone in diabetic patients with higher risk
of cardiovascular diseases, the incremental cost-
effectiveness ratio comparing pioglitazone and rosigli-
tazone may be lowered.
Source of ﬁnancial support: A grant from Thailand Research
Fund.
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